Intellipharmaceutics International Inc. (IPCIF)
Market Cap | 3.19M |
Revenue (ttm) | 176,838 |
Net Income (ttm) | -5.10M |
Shares Out | 33.09M |
EPS (ttm) | -0.16 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 295 |
Open | 0.0965 |
Previous Close | 0.1090 |
Day's Range | 0.0965 - 0.0965 |
52-Week Range | 0.0800 - 0.3000 |
Beta | 1.23 |
Analysts | Sell |
Price Target | n/a |
Earnings Date | n/a |
About IPCIF
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
No stock price forecast available yet.
News
Intellipharmaceutics Reports Director Election Results
TORONTO, ON / ACCESSWIRE / May 27, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the resea...
Intellipharmaceutics Announces First Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / April 14, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the r...
Intellipharmaceutics Announces Fiscal Year 2021 Results
TORONTO, ON / ACCESSWIRE / February 28, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the ...
Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead
TORONTO, ON / ACCESSWIRE / January 13, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Comments on Recent Trading Activity
TORONTO, ON / ACCESSWIRE / December 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the ...
Intellipharmaceutics Announces Third Quarter 2021 Results
TORONTO, ON / ACCESSWIRE / October 15, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Kim Spencer McPhee Barristers, P.C. Publishes This Notice of Certification and Notice of Hearing for Settlement Appro...
TORONTO--(BUSINESS WIRE)--Kim Spencer McPhee Barristers, P.C. today announces a proposed securities class action settlement regarding Intellipharmaceutics International Inc. (“IPCI”). In 2019, a propose...
Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement
TORONTO, ON / ACCESSWIRE / April 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the r...
Intellipharmaceutics Announces First Quarter 2021 Results
TORONTO, ON / ACCESSWIRE / April 14, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the resear...
Intellipharmaceutics Announces Fiscal Year 2020 Results
TORONTO, ON / ACCESSWIRE / March 1, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re...